Register

COURSE DESCRIPTION: 
Please join us for a conference on Lewy Body Disorders: Diagnosis and Management Across the DLB–PDD Spectrum with G. Peter Gliebus, M.D., FAAN, Dr. Gliebus will Recognize the core clinical features of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), and differentiate them from Alzheimer’s disease and other atypical dementias, apply current diagnostic criteria and supportive biomarkers (DaT-SPECT, MIBG, PSG-confirmed RBD, and emerging α-synuclein seed amplification assays) in routine practice, and implement evidence-based treatment strategies for cognition, neuropsychiatric symptoms (hallucinations, fluctuations), parkinsonism, sleep, and autonomic dysfunction.

TARGET AUDIENCE:
Internal Medicine Physicians, Pharmacists, Physician Assistants, Residents,  Advanced Practice Registered Nurses, and all other interested healthcare providers

LEARNING OBJECTIVES:

• Recognize the core clinical features of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD), and differentiate them from Alzheimer’s disease and other atypical dementias.
• Apply current diagnostic criteria and supportive biomarkers (DaT-SPECT, MIBG, PSG-confirmed RBD, and emerging α-synuclein seed amplification assays) in routine practice.
• Implement evidence-based treatment strategies for cognition, neuropsychiatric symptoms (hallucinations, fluctuations), parkinsonism, sleep, and autonomic dysfunction.

FACULTY AND DISCLOSURES:

G. Peter Gliebus, M.D., FAAN
Chief of Neurology
Medical Director, Cognitive and Behavioral Program
Baptist health - Marcus Neurosciences Institute
Associate Professor of Neurology
Florida Atlantic University, CE Schmidt College of Medicine
Boca Raton, Florida

G. Peter Gliebus, M.D., FAAN, faculty for this educational activity, indicated that he is a speaker for Eisai Pharmaceuticals. Dr. Gliebus has indicated that the presentation or discussion will include off-label or unapproved product usage.  All of the relevant financial relationships listed for these individuals have been mitigated.

John F. Rubin, M.D., FACP, director of this educational activity, has indicated that he is a shareholder in AstraZeneca and Bristol-Myers Squibb. All of the relevant financial relationships listed for this individual have been mitigated.

Non-faculty contributors and others involved in the planning, development and editing/review of the content have no relevant financial relationships with ineligible companies* to disclose.

*Ineligible companies – Companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Disclosure Policy and Disclaimer

ACCREDITATION STATEMENTS AND CREDITS

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.

Baptist Health South Florida designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

This activity has been approved for 1 credit hour, CE Broker Course #20-1296402, by the Florida Boards of Medicine, Podiatry, Osteopathic Medicine and Physician Assistants.  

This activity has also been approved for 1 credit for Nurse Practitioners, Nurses, Pharmacists and Pharmacy Techs, Laboratory Personnel, Athletic Trainers and Respiratory Techs. Baptist Health South Florida CE Broker Provider #50-182.